Reuters logo
Momenta seeks $938 million from Amphastar at drug patent trial's end
July 20, 2017 / 10:44 PM / in 3 months

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

The damages request came at the end of a trial in federal court in Boston in a long-running lawsuit pitting Cambridge, Massachusetts-based biopharmaceutical company Momenta and its partner, Novartis AG’s Sandoz unit, against Amphastar.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2vGmZ7F

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below